What's new? Log in Free sign up

Tyra Biosciences (TYRA)

Company Profile

Company profile

Ticker

TYRA

Exchange

Website

CEO

Dr. Todd Harris Ph.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

Wealthbridge Acquisition Ltd

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

831476348

TYRA stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

HC Wainwright & Co.

Latest filings (excl ownership)

View all

Departure of Directors or Certain Officers

Quarterly report

7 Nov 24

Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

Departure of Directors or Certain Officers

Unregistered Sales of Equity Securities

Quarterly report

7 Aug 24

Tyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights

Material Modifications to Rights of Security Holders

Quarterly report

9 May 24

Latest ownership filings

View all

Nina S Kjellson

Notice of proposed sale of securities

Nina S Kjellson

Notice of proposed sale of securities

Boxer Capital Management, LLC

Notice of proposed sale of securities

Notice of proposed sale of securities

Nina S Kjellson

Notice of proposed sale of securities

Boxer Capital Management, LLC

Financial summary

Financial statements Chart TYRA financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	104.89 mm	104.89 mm	104.89 mm	104.89 mm	104.89 mm	104.89 mm
Cash burn (monthly)	(no burn)	9.31 mm	9.53 mm	8.34 mm	5.97 mm	5.31 mm
Cash used (since last report)	n/a	37.48 mm	38.37 mm	33.57 mm	24.01 mm	21.37 mm
Cash remaining	n/a	67.41 mm	66.52 mm	71.32 mm	80.88 mm	83.52 mm
Runway (months of cash)	n/a	7.2	7.0	8.6	13.6	15.7

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

TYRA institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	101	83	+21.7%
Opened positions	27	19	+42.1%
Closed positions	9	14	-35.7%
Increased positions	31	30	+3.3%
Reduced positions	20	16	+25.0%

13F shares	Current	Prev Q	Change
Total value	1.10 tn	745.50 bn	+48.2%
Total shares	63.79 mm	59.82 mm	+6.6%
Total puts	1.10 k	0.00	NEW
Total calls	352.90 k	0.00	NEW
Total put/call ratio	0.0	–	–

Largest owners	Shares	Value	Change
Ra Capital Management	10.42 mm	$244.89 bn	0.0%
Boxer Capital	6.45 mm	$151.60 bn	0.0%
Biotechnology Value Fund L P	4.66 mm	$74.44 mm	+88.5%
BVF	4.66 mm	$109.58 bn	0.0%
Canaan Partners XI	4.41 mm	$103.68 bn	0.0%
Alta Partners NextGen Fund II Management	4.08 mm	$81.24 mm	0.0%
Nextech Vi Oncology SCSP	4.06 mm	$64.77 mm	+61.0%
Nextech Invest	4.06 mm	$95.35 bn	0.0%
Canaan XI	3.94 mm	$55.39 mm	0.0%
FMR	3.37 mm	$79.30 bn	+0.8%

Largest transactions	Shares	Bought/sold	Change
Biotechnology Value Fund L P	4.66 mm	+2.19 mm	+88.5%
Nextech Vi Oncology SCSP	4.06 mm	+1.54 mm	+61.0%
BlackRock	1.52 mm	+1.52 mm	NEW
BLK BlackRock	0.00	-1.42 mm	EXIT
JHG Janus Henderson	1.07 mm	+1.07 mm	NEW
Perceptive Advisors	511.23 k	-496.14 k	-49.3%
Avidity Partners Management	0.00	-373.00 k	EXIT
Adage Capital Partners GP, L.L.C.	200.00 k	+200.00 k	NEW
Sio Capital Management	400.87 k	-199.42 k	-33.2%
ExodusPoint Capital Management	0.00	-170.72 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

TYRA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
23 Jan 25	Nina S Kjellson	Common Stock	Sell	Dispose S	Yes	No	16.2624	4,825	78.47 k	3,702,595
21 Jan 25	Nina S Kjellson	Common Stock	Sell	Dispose S	Yes	No	16.3626	3,993	65.34 k	3,707,420
17 Jan 25	Nina S Kjellson	Common Stock	Sell	Dispose S	Yes	No	16.4001	461	7.56 k	447,396
17 Jan 25	Nina S Kjellson	Common Stock	Sell	Dispose S	Yes	No	16.4001	12,808	210.05 k	3,711,413
16 Jan 25	Nina S Kjellson	Common Stock	Sell	Dispose S	Yes	No	16.287	835	13.60 k	447,857
16 Jan 25	Nina S Kjellson	Common Stock	Sell	Dispose S	Yes	No	16.287	6,944	113.10 k	3,724,221
25 Nov 24	Nina S Kjellson	Common Stock	Sell	Dispose S	Yes	No	16.8386	566	9.53 k	448,692
25 Nov 24	Nina S Kjellson	Common Stock	Sell	Dispose S	Yes	No	16.8386	4,706	79.24 k	3,731,165
8 Nov 24	Ra Capital Management	Common Stock	Buy	Acquire P	Yes	No	16.25	1,220,681	19.84 mm	8,697,956
7 Nov 24	Nina S Kjellson	Common Stock	Sell	Dispose S	Yes	No	17.3181	2,371	41.06 k	449,258

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $30 Price Target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Tyra Biosciences (NASDAQ:TYRA) with a Buy and maintains $30 price target.

UBS Initiates Coverage On Tyra Biosciences with Buy Rating, Announces Price Target of $28

UBS analyst Eliana Merle initiates coverage on Tyra Biosciences (NASDAQ:TYRA) with a Buy rating and announces Price Target of $28.

Neumora Therapeutics, XPeng And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

HC Wainwright & Co. Maintains Buy on Tyra Biosciences, Lowers Price Target to $30

Tyra Biosciences Q3 EPS $(0.41) Misses $(0.40) Estimate

Press releases

From Benzinga Pro

Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors

CARLSBAD, Calif., Jan. 29, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in

Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium

CARLSBAD, Calif., Jan. 22, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

-TYRA appoints urologic oncologist, Erik Goluboff, M.D., as SVP, Clinical Development to lead NMIBC- -First patient expected to be dosed in SURF302 in Q2 2025- CARLSBAD, Calif., Jan. 10, 2025 /PRNewswire/ -- Tyra

Tyra Biosciences to Present at Upcoming Investor Conferences

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.